Advances in pathogenesis and nanoparticles (NPs)-mediated treatment of psoriasis

Front Immunol. 2022 Dec 22:13:1089262. doi: 10.3389/fimmu.2022.1089262. eCollection 2022.

Abstract

Psoriasis is a chronic papulosquamous skin disease with an autoimmune pathogenic traits and strong genetic predisposition. In the past few decades, with the rapid development of molecular biology and cell biology, the inherent pathogenesis of psoriasis has been gradually elucidated, in which cytokine inflammatory loops, cell signaling pathways, and epigenetic factors such as miRNAs have been demonstrated to play important roles in regulating the development and progression of psoriasis. More importantly, understanding the pathogenesis of psoriasis has promoted the development of effective treatment for psoriasis. In this review, we systemically summarized the molecular mechanisms regulating the development and progression psoriasis, introduced various therapeutics used for clinical psoriasis therapy, and highlighted the recent advances in nanoparticles (NPs)-mediated drug delivery for psoriasis treatment.

Keywords: autoimmune disease; nanoparticles; pathogenesis; psoriasis; psoriasis treatment.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Genetic Predisposition to Disease
  • Humans
  • MicroRNAs* / pharmacology
  • Nanoparticles*
  • Psoriasis* / drug therapy
  • Psoriasis* / etiology
  • Skin

Substances

  • MicroRNAs